Strategies to improve vaccine efficacy against tuberculosis by targeting innate immunity

Frontiers in Immunology

Volumn 8, Issue DEC, 2017, Pages

  Schaible, Ulrich E ^a   Linnemann, Lara ^a   Redinger, Natalja ^a   Patin, Emmanuel C ^a,b   Dallenga, Tobias ^a  

^a RESEARCH CENTER BORSTEL   (Germany)

^b THE FRANCIS CRICK INSTITUTE   (United Kingdom)

Author keywords

CD1; Cell death; Host directed therapy; IL 10; Mycobacterium tuberculosis; Neutrophils; Tuberculosis; Vaccine

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; VACCINE;

ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; CELLULAR IMMUNITY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INNATE IMMUNITY; LUNG LAVAGE; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS COMPLEX; NEUTROPHIL; NONHUMAN; REGULATORY T LYMPHOCYTE; SHORT SURVEY; TUBERCULOSIS; VACCINATION;

EID: 85037672053     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.01755     Document Type: Short Survey

References (148)

1. WHO. World Health Organization: Global Tuberculosis Report. 20th ed. Geneva: WHO Press (2016)
2. Mangtani P, Abubakar I, Ariti C, Beynon R, Pimpin L, Fine PE, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis (2014) 58:470-80. doi:10.1093/cid/cit790
3. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet (2013) 381:1021-8. doi:10.1016/S0140-6736(13)60177-4
4. Belisle JT, Vissa VD, Sievert T, Takayama K, Brennan PJ, Besra GS. Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science (1997) 276:1420-2. doi:10.1126/science.276.5317.1420
5. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med (2004) 10:1240-4. doi:10.1038/nm1128
6. Upadhyay P. Tuberculosis vaccine trials. Lancet (2013) 381:2253-4. doi:10.1016/S0140-6736(13)61482-8
7. Andersen P, Doherty TM. The success and failure of BCG-implications for a novel tuberculosis vaccine. Nat Rev Microbiol (2005) 3:656-62. doi:10.1038/nrmicro1211
8. Eum SY, Kong JH, Hong MS, Lee YJ, Kim JH, Hwang SH, et al. Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest (2010) 137:122-8. doi:10.1378/chest.09-0903
9. Berry MP, Graham CM, Mcnab FW, Xu Z, Bloch SA, Oni T, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature (2010) 466:973-7. doi:10.1038/nature09247
10. Gopal R, Monin L, Torres D, Slight S, Mehra S, McKenna KC, et al. S100A8/A9 proteins mediate neutrophilic inflammation and lung pathology during tuberculosis. Am J Respir Crit Care Med (2013) 188:1137-46. doi:10.1164/rccm.201304-0803OC
11. Dallenga T, Schaible UE. Neutrophils in tuberculosis-first line of defence or booster of disease and targets for host-directed therapy? Pathog Dis (2016) 74:ftw012. doi:10.1093/femspd/ftw012
12. Irwin SM, Gruppo V, Brooks E, Gilliland J, Scherman M, Reichlen MJ, et al. Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas. Antimicrob Agents Chemother (2014) 58:4026-34. doi:10.1128/AAC.02565-14
13. Vilaplana C, Marzo E, Tapia G, Diaz J, Garcia V, Cardona PJ. Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. J Infect Dis (2013) 208:199-202. doi:10.1093/infdis/jit152
14. Yeremeev V, Linge I, Kondratieva T, Apt A. Neutrophils exacerbate tuberculosis infection in genetically susceptible mice. Tuberculosis (Edinb) (2015) 95:447-51. doi:10.1016/j.tube.2015.03.007
15. Abadie V, Badell E, Douillard P, Ensergueix D, Leenen PJ, Tanguy M, et al. Neutrophils rapidly migrate via lymphatics after Mycobacterium bovis BCG intradermal vaccination and shuttle live bacilli to the draining lymph nodes. Blood (2005) 106:1843-50. doi:10.1182/blood-2005-03-1281
16. Schoenen H, Bodendorfer B, Hitchens K, Manzanero S, Werninghaus K, Nimmerjahn F, et al. Cutting edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. J Immunol (2010) 184:2756-60. doi:10.4049/jimmunol.0904013
17. Maletto BA, Ropolo AS, Alignani DO, Liscovsky MV, Ranocchia RP, Moron VG, et al. Presence of neutrophil-bearing antigen in lymphoid organs of immune mice. Blood (2006) 108:3094-102. doi:10.1182/blood-2006-04-016659
18. Puga I, Cols M, Barra CM, He B, Cassis L, Gentile M, et al. B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. Nat Immunol (2011) 13:170-80. doi:10.1038/ni.2194
19. Nagelkerke SQ, Aan De Kerk DJ, Jansen MH, Van Den Berg TK, Kuijpers TW. Failure to detect functional neutrophil B helper cells in the human spleen. PLoS One (2014) 9:e88377. doi:10.1371/journal.pone.0088377
20. Achkar JM, Chan J, Casadevall A. B cells and antibodies in the defense against Mycobacterium tuberculosis infection. Immunol Rev (2015) 264:167-81. doi:10.1111/imr.12276
21. Jacobs AJ, Mongkolsapaya J, Screaton GR, McShane H, Wilkinson RJ. Antibodies and tuberculosis. Tuberculosis (Edinb) (2016) 101:102-13. doi:10.1016/j.tube.2016.08.001
22. Matsushima H, Geng S, Lu R, Okamoto T, Yao Y, Mayuzumi N, et al. Neutrophil differentiation into a unique hybrid population exhibiting dual phenotype and functionality of neutrophils and dendritic cells. Blood (2013) 121:1677-89. doi:10.1182/blood-2012-07-445189
23. Di Pilato M, Mejias-Perez E, Zonca M, Perdiguero B, Gomez CE, Trakala M, et al. NFkappaB activation by modified vaccinia virus as a novel strategy to enhance neutrophil migration and HIV-specific T-cell responses. Proc Natl Acad Sci U S A (2015) 112:E1333-42. doi:10.1073/pnas.1424341112
24. Trentini MM, De Oliveira FM, Kipnis A, Junqueira-Kipnis AP. The role of neutrophils in the induction of specific Th1 and Th17 during vaccination against tuberculosis. Front Microbiol (2016) 7:898. doi:10.3389/fmicb.2016.00898
25. Yang CW, Strong BS, Miller MJ, Unanue ER. Neutrophils influence the level of antigen presentation during the immune response to protein antigens in adjuvants. J Immunol (2010) 185:2927-34. doi:10.4049/jimmunol.1001289
26. Yang CW, Unanue ER. Neutrophils control the magnitude and spread of the immune response in a thromboxane A2-mediated process. J Exp Med (2013) 210:375-87. doi:10.1084/jem.20122183
27. Kabashima K, Murata T, Tanaka H, Matsuoka T, Sakata D, Yoshida N, et al. Thromboxane A2 modulates interaction of dendritic cells and T cells and regulates acquired immunity. Nat Immunol (2003) 4:694-701. doi:10.1038/ni943
28. Restifo NP. Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity. Curr Opin Immunol (2000) 12:597-603. doi:10.1016/S0952-7915(00)00148-5
29. Schaible UE, Winau F, Sieling PA, Fischer K, Collins HL, Hagens K, et al. Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. Nat Med (2003) 9:1039-46. doi:10.1038/nm906
30. Winau F, Weber S, Sad S, De Diego J, Hoops SL, Breiden B, et al. Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis. Immunity (2006) 24:105-17. doi:10.1016/j.immuni.2005.12.001
31. Herbst S, Schaible UE, Schneider BE. Interferon gamma activated macrophages kill mycobacteria by nitric oxide induced apoptosis. PLoS One (2011) 6:e19105. doi:10.1371/journal.pone.0019105
32. Corleis B, Korbel D, Wilson R, Bylund J, Chee R, Schaible UE. Escape of Mycobacterium tuberculosis from oxidative killing by neutrophils. Cell Microbiol (2012) 14:1109-21. doi:10.1111/j.1462-5822.2012.01783.x
33. Lai YM, Mohammed KA, Nasreen N, Baumuratov A, Bellew BF, Antony VB. Induction of cell cycle arrest and apoptosis by BCG infection in cultured human bronchial airway epithelial cells. Am J Physiol Lung Cell Mol Physiol (2007) 293:L393-401. doi:10.1152/ajplung.00392.2006
34. Wong KW, Jacobs WR Jr. Postprimary tuberculosis and macrophage necrosis: is there a big ConNECtion? MBio (2016) 7:e01589-15. doi:10.1128/mBio.01589-15
35. Behar SM, Martin CJ, Booty MG, Nishimura T, Zhao X, Gan HX, et al. Apoptosis is an innate defense function of macrophages against Mycobacterium tuberculosis. Mucosal Immunol (2011) 4:279-87. doi:10.1038/mi.2011.3
36. Aporta A, Arbues A, Aguilo JI, Monzon M, Badiola JJ, De Martino A, et al. Attenuated Mycobacterium tuberculosis SO2 vaccine candidate is unable to induce cell death. PLoS One (2012) 7:e45213. doi:10.1371/journal.pone.0045213
37. Augenstreich J, Arbues A, Simeone R, Haanappel E, Wegener A, Sayes F, et al. ESX-1 and phthiocerol dimycocerosates of Mycobacterium tuberculosis act in concert to cause phagosomal rupture and host cell apoptosis. Cell Microbiol (2017) 19:e12726. doi:10.1111/cmi.12726
38. Simeone R, Bobard A, Lippmann J, Bitter W, Majlessi L, Brosch R, et al. Phagosomal rupture by Mycobacterium tuberculosis results in toxicity and host cell death. PLoS Pathog (2012) 8:e1002507. doi:10.1371/journal.ppat.1002507
39. Repasy T, Lee J, Marino S, Martinez N, Kirschner DE, Hendricks G, et al. Intracellular bacillary burden reflects a burst size for Mycobacterium tuberculosis in vivo. PLoS Pathog (2013) 9:e1003190. doi:10.1371/journal.ppat.1003190
40. Grode L, Seiler P, Baumann S, Hess J, Brinkmann V, Nasser Eddine A, et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest (2005) 115:2472-9. doi:10.1172/JCI24617
41. Scheffer SR, Nave H, Korangy F, Schlote K, Pabst R, Jaffee EM, et al. Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int J Cancer (2003) 103:205-11. doi:10.1002/ijc.10777
42. Polyzoidis S, Tuazon J, Brazil L, Beaney R, Al-Sarraj ST, Doey L, et al. Active dendritic cell immunotherapy for glioblastoma: current status and challenges. Br J Neurosurg (2015) 29:197-205. doi:10.3109/02688697.2014.994473
43. Garg AD, Vandenberk L, Koks C, Verschuere T, Boon L, Van Gool SW, et al. Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma. Sci Transl Med (2016) 8:328ra27. doi:10.1126/scitranslmed.aae0105
44. Aaes TL, Kaczmarek A, Delvaeye T, De Craene B, De Koker S, Heyndrickx L, et al. Vaccination with necroptotic cancer cells induces efficient anti-tumor immunity. Cell Rep (2016) 15:274-87. doi:10.1016/j.celrep.2016.03.037
45. Wang J, Li B, Wu MX. Effective and lesion-free cutaneous influenza vaccination. Proc Natl Acad Sci U S A (2015) 112:5005-10. doi:10.1073/pnas.1500408112
46. Chen X, Kositratna G, Zhou C, Manstein D, Wu MX. Micro-fractional epidermal powder delivery for improved skin vaccination. J Control Release (2014) 192:310-6. doi:10.1016/j.jconrel.2014.08.006
47. Huang S, Cheng T-Y, Young DC, Layre E, Madigan CA, Shires J, et al. Discovery of deoxyceramides and diacylglycerols as CD1b scaffold lipids among diverse groove-blocking lipids of the human CD1 system. Proc Natl Acad Sci U S A (2011) 108:19335-40. doi:10.1073/pnas.1112969108
48. de Jong A. Activation of human T cells by CD1 and self-lipids. Immunol Rev (2015) 267:16-29. doi:10.1111/imr.12322
49. Moody DB, Zajonc DM, Wilson IA. Anatomy of CD1-lipid antigen complexes. Nat Rev Immunol (2005) 5:387-99. doi:10.1038/nri1605
50. Van Rhijn I, Moody DB. CD1 and mycobacterial lipids activate human T cells. Immunol Rev (2015) 264:138-53. doi:10.1111/imr.12253
51. Wu L, Van Kaer L. Natural killer T cells and autoimmune disease. Curr Mol Med (2009) 9:4-14. doi:10.2174/156652409787314534
52. Swann JB, Coquet JMC, Smyth MJ, Godfrey DI. CD1-Restricted T Cells and Tumor Immunity. Berlin, Heidelberg: Springer Berlin Heidelberg (2007)
53. Libero GD, Mori L. The T-cell response to lipid antigens of Mycobacterium tuberculosis. Front Immunol (2014) 5:1-1. doi:10.3389/fimmu.2014.00219
54. Beckman EM, Porcelli SA, Morita CT, Behar SM, Furlong ST, Brenner MB. Recognition of a lipid antigen by CD1-restricted alpha beta+ T cells. Nature (1994) 372:691-4. doi:10.1038/372691a0
55. Gilleron M, Stenger S, Mazorra Z, Wittke F, Mariotti S, Bohmer G, et al. Diacylated sulfoglycolipids are novel mycobacterial antigens stimulating CD1-restricted T cells during infection with Mycobacterium tuberculosis. J Exp Med (2004) 199:649-59. doi:10.1084/jem.20031097
56. Sieling PA, Jullien D, Dahlem M, Tedder TF, Rea TH, Modlin RL, et al. CD1 expression by dendritic cells in human leprosy lesions: correlation with effective host immunity. J Immunol (1999) 162:1851-8
57. Ulrichs T, Moody DB, Grant E, Kaufmann SHE, Porcelli SA. T-cell responses to CD1-presented lipid antigens in humans with Mycobacterium tuberculosis infection. Infect Immun (2003) 71:3076-87. doi:10.1128/IAI.71.6.3076-3087.2003
58. Hiromatsu K, Dascher CC, Leclair KP, Sugita M, Furlong ST, Brenner MB, et al. Induction of CD1-restricted immune responses in guinea pigs by immunization with mycobacterial lipid antigens. J Immunol (2002) 169:330-9. doi:10.4049/jimmunol.169.1.330
59. Dascher CC, Hiromatsu K, Xiong X, Morehouse C, Watts G, Liu G, et al. Immunization with a mycobacterial lipid vaccine improves pulmonary pathology in the guinea pig model of tuberculosis. Int Immunol (2003) 15(8):915-25. doi:10.1093/intimm/dxg091
60. Larrouy-Maumus G, Layre E, Clark S, Prandi J, Rayner E, Lepore M, et al. Protective efficacy of a lipid antigen vaccine in a guinea pig model of tuberculosis. Vaccine (2017) 35:1395-402. doi:10.1016/j.vaccine.2017.01.079
61. Galli G, Nuti S, Tavarini S, Galli-Stampino L, De Lalla C, Casorati G, et al. CD1d-restricted help to B cells by human invariant natural killer T lymphocytes. J Exp Med (2003) 197:1051-7. doi:10.1084/jem.20021616
62. Leadbetter EA, Brigl M, Illarionov P, Cohen N, Luteran MC, Pillai S, et al. NK T cells provide lipid antigen-specific cognate help for B cells. Proc Natl Acad Sci U S A (2008) 105:8339-44. doi:10.1073/pnas.0801375105
63. Nguyen TK, Wieland W, Santema W, Hoeboer J, Van Eden W, Rutten V, et al. Immune response of cattle immunized with a conjugate of the glycolipid glucose monomycolate and protein. Vet Immunol Immunopathol (2011) 142:265-70. doi:10.1016/j.vetimm.2011.05.016
64. Di Nardo A, Wertz P, Giannetti A, Seidenari S. Ceramide and cholesterol composition of the skin of patients with atopic dermatitis. Acta Derm Venereol (1998) 78:27-30. doi:10.1080/00015559850135788
65. Motta S, Monti M, Sesana S, Caputo R, Carelli S, Ghidoni R. Ceramide composition of the psoriatic scale. Biochim Biophys Acta (1993) 1182:147-51. doi:10.1016/0925-4439(93)90135-N
66. Gadola SD, Zaccai NR, Harlos K, Shepherd D, Castro-Palomino JC, Ritter G, et al. Structure of human CD1b with bound ligands at 2.3 Å, a maze for alkyl chains. Nat Immunol (2002) 3:721-6. doi:10.1038/ni821
67. Hung J-T, Huang J-R, Yu AL. Tailored design of NKT-stimulatory glycolipids for polarization of immune responses. J Biomed Sci (2017) 24:22-22. doi:10.1186/s12929-017-0325-0
68. Miyamoto K, Miyake S, Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature (2001) 413:531-4. doi:10.1038/35097097
69. Chang Y-J, Huang J-R, Tsai Y-C, Hung J-T, Wu D, Fujio M, et al. Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids. Proc Natl Acad Sci U S A (2007) 104:10299-304. doi:10.1073/pnas.0703824104
70. Schmieg J, Yang G, Franck RW, Tsuji M. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand a-galactosylceramide. J Exp Med (2003) 198:1631-41. doi:10.1084/jem.20031192
71. Carlin G, Djursäter R. Peroxidation of phospholipids promoted by myeloperoxidase. Free Radic Res Commun (1988) 4:251-7. doi:10.3109/10715768809055150
72. Claster S, Chiu DT, Quintanilha A, Lubin B. Neutrophils mediate lipid peroxidation in human red cells. Blood (1984) 64:1079-84
73. Niki E. Lipid peroxidation: physiological levels and dual biological effects. Free Radic Biol Med (2009) 47:469-84. doi:10.1016/j.freeradbiomed.2009.05.032
74. Agea E, Russano A, Bistoni O, Mannucci R, Nicoletti I, Corazzi L, et al. Human CD1-restricted T cell recognition of lipids from pollens. J Exp Med (2005) 202:295-308. doi:10.1084/jem.20050773
75. Gong J, Stenger S, Zack JA, Jones BE, Bristol GC, Modlin RL, et al. Isolation of Mycobacterium-reactive CD1-restricted T cells from patients with human immunodeficiency virus infection. J Clin Invest (1998) 101:383-9. doi:10.1172/JCI318
76. Gopal R, Lin Y, Obermajer N, Slight S, Nuthalapati N, Ahmed M, et al. IL-23-dependent IL-17 drives Th1-cell responses following Mycobacterium bovis BCG vaccination. Eur J Immunol (2012) 42:364-73. doi:10.1002/eji.201141569
77. Pitt JM, Stavropoulos E, Redford PS, Beebe AM, Bancroft GJ, Young DB, et al. Blockade of IL-10 signaling during bacillus Calmette-Guerin vaccination enhances and sustains Th1, Th17, and innate lymphoid IFN-gamma and IL-17 responses and increases protection to Mycobacterium tuberculosis infection. J Immunol (2012) 189:4079-87. doi:10.4049/jimmunol.1201061
78. Abdalla AE, Li Q, Xie L, Xie J. Biology of IL-27 and its role in the host immunity against Mycobacterium tuberculosis. Int J Biol Sci (2015) 11:168-75. doi:10.7150/ijbs.10464
79. Moore KW, De Waal Malefyt R, Coffman RL, O'garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol (2001) 19:683-765. doi:10.1146/annurev.immunol.19.1.683
80. Belkaid Y, Hoffmann KF, Mendez S, Kamhawi S, Udey MC, Wynn TA, et al. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med (2001) 194:1497-506. doi:10.1084/jem.194.10.1497
81. Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, Mc Gavern DB, Oldstone MB. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med (2006) 12:1301-9. doi:10.1038/nm1492
82. Soares AP, Scriba TJ, Joseph S, Harbacheuski R, Murray RA, Gelderbloem SJ, et al. Bacillus Calmette-Guerin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles. J Immunol (2008) 180:3569-77. doi:10.4049/jimmunol.180.5.3569
83. Lalor MK, Smith SG, Floyd S, Gorak-Stolinska P, Weir RE, Blitz R, et al. Complex cytokine profiles induced by BCG vaccination in UK infants. Vaccine (2010) 28:1635-41. doi:10.1016/j.vaccine.2009.11.004
84. Akkoc T, Aydogan M, Yildiz A, Karakoc-Aydiner E, Eifan A, Keles S, et al. Neonatal BCG vaccination induces IL-10 production by CD4+ CD25+ T cells. Pediatr Allergy Immunol (2010) 21:1059-63. doi:10.1111/j.1399-3038.2010.01051.x
85. Zhang X, Majlessi L, Deriaud E, Leclerc C, Lo-Man R. Coactivation of Syk kinase and MyD88 adaptor protein pathways by bacteria promotes regulatory properties of neutrophils. Immunity (2009) 31:761-71. doi:10.1016/j.immuni.2009.09.016
86. Lindenstrom T, Woodworth J, Dietrich J, Aagaard C, Andersen P, Agger EM. Vaccine-induced th17 cells are maintained long-term postvaccination as a distinct and phenotypically stable memory subset. Infect Immun (2012) 80:3533-44. doi:10.1128/IAI.00550-12
87. Desel C, Werninghaus K, Ritter M, Jozefowski K, Wenzel J, Russkamp N, et al. The Mincle-activating adjuvant TDB induces MyD88-dependent Th1 and Th17 responses through IL-1R signaling. PLoS One (2013) 8:e53531. doi:10.1371/journal.pone.0053531
88. Schweneker K, Gorka O, Schweneker M, Poeck H, Tschopp J, Peschel C, et al. The mycobacterial cord factor adjuvant analogue trehalose-6,6'-dibehenate (TDB) activates the Nlrp3 inflammasome. Immunobiology (2013) 218:664-73. doi:10.1016/j.imbio.2012.07.029
89. Decout A, Silva-Gomes S, Drocourt D, Barbe S, Andre I, Cueto FJ, et al. Rational design of adjuvants targeting the C-type lectin Mincle. Proc Natl Acad Sci U S A (2017) 114:2675-80. doi:10.1073/pnas.1612421114
90. Patin EC, Willcocks S, Orr S, Ward TH, Lang R, Schaible UE. Mincle-mediated anti-inflammatory IL-10 response counter-regulates IL-12 in vitro. Innate Immun (2016) 22(3):181-5. doi:10.1177/1753425916636671
91. Torrado E, Cooper AM. Cytokines in the balance of protection and pathology during mycobacterial infections. Adv Exp Med Biol (2013) 783:121-40. doi:10.1007/978-1-4614-6111-1_7
92. Alter G, Sekaly RP. Beyond adjuvants: antagonizing inflammation to enhance vaccine immunity. Vaccine (2015) 33(Suppl 2):B55-9. doi:10.1016/j.vaccine.2015.03.058
93. du Plessis N, Loebenberg L, Kriel M, Von Groote-Bidlingmaier F, Ribechini E, Loxton AG, et al. Increased frequency of myeloid-derived suppressor cells during active tuberculosis and after recent Mycobacterium tuberculosis infection suppresses T-cell function. Am J Respir Crit Care Med (2013) 188:724-32. doi:10.1164/rccm.201302-0249OC
94. Yang B, Wang X, Jiang J, Zhai F, Cheng X. Identification of CD244-expressing myeloid-derived suppressor cells in patients with active tuberculosis. Immunol Lett (2014) 158:66-72. doi:10.1016/j.imlet.2013.12.003
95. El Daker S, Sacchi A, Tempestilli M, Carducci C, Goletti D, Vanini V, et al. Granulocytic myeloid derived suppressor cells expansion during active pulmonary tuberculosis is associated with high nitric oxide plasma level. PLoS One (2015) 10:e0123772. doi:10.1371/journal.pone.0123772
96. Knaul JK, Jorg S, Oberbeck-Mueller D, Heinemann E, Scheuermann L, Brinkmann V, et al. Lung-residing myeloid-derived suppressors display dual functionality in murine pulmonary tuberculosis. Am J Respir Crit Care Med (2014) 190:1053-66. doi:10.1164/rccm.201405-0828OC
97. Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol (2008) 181:4666-75. doi:10.4049/jimmunol.181.7.4666
98. Edgeworth J, Gorman M, Bennett R, Freemont P, Hogg N. Identification of p8,14 as a highly abundant heterodimeric calcium binding protein complex of myeloid cells. J Biol Chem (1991) 266:7706-13
99. Xu D, Li Y, Li X, Wei LL, Pan Z, Jiang TT, et al. Serum protein S100A9, SOD3, and MMP9 as new diagnostic biomarkers for pulmonary tuberculosis by iTRAQ-coupled two-dimensional LC-MS/MS. Proteomics (2015) 15:58-67. doi:10.1002/pmic.201400366
100. Kang DD, Lin Y, Moreno JR, Randall TD, Khader SA. Profiling early lung immune responses in the mouse model of tuberculosis. PLoS One (2011) 6:e16161. doi:10.1371/journal.pone.0016161
101. Kraakman MJ, Lee MK, Al-Sharea A, Dragoljevic D, Barrett TJ, Montenont E, et al. Neutrophil-derived S100 calcium-binding proteins A8/A9 promote reticulated thrombocytosis and atherogenesis in diabetes. J Clin Invest (2017) 127:2133-47. doi:10.1172/JCI92450
102. van den Bosch MH, Blom AB, Schelbergen RF, Koenders MI, Van De Loo FA, Van Den Berg WB, et al. Alarmin S100A9 induces proinflammatory and catabolic effects predominantly in the M1 macrophages of human osteoarthritic synovium. J Rheumatol (2016) 43:1874-84. doi:10.3899/jrheum.160270
103. Schelbergen RF, Geven EJ, Van Den Bosch MH, Eriksson H, Leanderson T, Vogl T, et al. Prophylactic treatment with S100A9 inhibitor paquinimod reduces pathology in experimental collagenase-induced osteoarthritis. Ann Rheum Dis (2015) 74:2254-8. doi:10.1136/annrheumdis-2014-206517
104. Deronic A, Helmersson S, Leanderson T, Ivars F. The quinoline-3-carboxamide paquinimod (ABR-215757) reduces leukocyte recruitment during sterile inflammation: leukocyte-and context-specific effects. Int Immunopharmacol (2014) 18:290-7. doi:10.1016/j.intimp.2013.12.008
105. Stenstrom M, Nyhlen HC, Torngren M, Liberg D, Sparre B, Tuvesson H, et al. Paquinimod reduces skin fibrosis in tight skin 1 mice, an experimental model of systemic sclerosis. J Dermatol Sci (2016) 83:52-9. doi:10.1016/j.jdermsci.2016.04.006
106. Chiacchio T, Casetti R, Butera O, Vanini V, Carrara S, Girardi E, et al. Characterization of regulatory T cells identified as CD4(+)CD25(high)CD39(+) in patients with active tuberculosis. Clin Exp Immunol (2009) 156:463-70. doi:10.1111/j.1365-2249.2009.03908.x
107. Sharma PK, Saha PK, Singh A, Sharma SK, Ghosh B, Mitra DK. FoxP3+ regulatory T cells suppress effector T-cell function at pathologic site in miliary tuberculosis. Am J Respir Crit Care Med (2009) 179:1061-70. doi:10.1164/rccm.200804-529OC
108. Pang H, Yu Q, Guo B, Jiang Y, Wan L, Li J, et al. Frequency of regulatory T-cells in the peripheral blood of patients with pulmonary tuberculosis from shanxi province, china. PLoS One (2013) 8:e65496. doi:10.1371/journal.pone.0065496
109. Shafiani S, Tucker-Heard G, Kariyone A, Takatsu K, Urdahl KB. Pathogen-specific regulatory T cells delay the arrival of effector T cells in the lung during early tuberculosis. J Exp Med (2010) 207:1409-20. doi:10.1084/jem.20091885
110. Chen CY, Huang D, Yao S, Halliday L, Zeng G, Wang RC, et al. IL-2 simultaneously expands Foxp3+ T regulatory and T effector cells and confers resistance to severe tuberculosis (TB): implicative Treg-T effector cooperation in immunity to TB. J Immunol (2012) 188:4278-88. doi:10.4049/jimmunol.1101291
111. Bhattacharya D, Dwivedi VP, Maiga M, Maiga M, Van Kaer L, Bishai WR, et al. Small molecule-directed immunotherapy against recurrent infection by Mycobacterium tuberculosis. J Biol Chem (2014) 289:16508-15. doi:10.1074/jbc.M114.558098
112. Bhattacharya D, Dwivedi VP, Kumar S, Reddy MC, Van KAER L, Moodley P, et al. Simultaneous inhibition of T helper 2 and T regulatory cell differentiation by small molecules enhances Bacillus Calmette-Guerin vaccine efficacy against tuberculosis. J Biol Chem (2014) 289:33404-11. doi:10.1074/jbc.M114.600452
113. Boer MC, Joosten SA, Ottenhoff TH. Regulatory T-cells at the interface between human host and pathogens in infectious diseases and vaccination. Front Immunol (2015) 6:217. doi:10.3389/fimmu.2015.00217
114. Dhiman R, Periasamy S, Barnes PF, Jaiswal AG, Paidipally P, Barnes AB, et al. NK1.1+ cells and IL-22 regulate vaccine-induced protective immunity against challenge with Mycobacterium tuberculosis. J Immunol (2012) 189:897-905. doi:10.4049/jimmunol.1102833
115. Luo Y, Jiang W, Da Z, Wang B, Hu L, Zhang Y, et al. Subunit vaccine candidate AMM down-regulated the regulatory T cells and enhanced the protective immunity of BCG on a suitable schedule. Scand J Immunol (2012) 75:293-300. doi:10.1111/j.1365-3083.2011.02666.x
116. Jaron B, Maranghi E, Leclerc C, Majlessi L. Effect of attenuation of Treg during BCG immunization on anti-mycobacterial Th1 responses and protection against Mycobacterium tuberculosis. PLoS One (2008) 3:e2833. doi:10.1371/journal.pone.0002833
117. Jasenosky LD, Scriba TJ, Hanekom WA, Goldfeld AE. T cells and adaptive immunity to Mycobacterium tuberculosis in humans. Immunol Rev (2015) 264:74-87. doi:10.1111/imr.12274
118. Urdahl KB, Shafiani S, Ernst JD. Initiation and regulation of T-cell responses in tuberculosis. Mucosal Immunol (2011) 4:288-93. doi:10.1038/mi.2011.10
119. Lewinsohn DA, Lewinsohn DM, Scriba TJ. Polyfunctional CD4+ T cells as targets for tuberculosis vaccination. Front Immunol (2017) 8:1262. doi:10.3389/fimmu.2017.01262
120. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The example of natural killer cells. Science (2011) 331:44-9. doi:10.1126/science.1198687
121. Paust S, von Andrian UH. Natural killer cell memory. Nat Immunol (2011) 12:500-8. doi:10.1038/ni.2032
122. Cerwenka A, Lanier LL. Natural killer cell memory in infection, inflammation and cancer. Nat Rev Immunol (2016) 16:112-23. doi:10.1038/nri.2015.9
123. O'Sullivan TE, Sun JC, Lanier LL. Natural killer cell memory. Immunity (2015) 43:634-45. doi:10.1016/j.immuni.2015.09.013
124. Choreno Parra JA, Martinez Zuniga N, Jimenez Zamudio LA, Jimenez Alvarez LA, Salinas Lara C, Zuniga J. Memory of natural killer cells: a new chance against Mycobacterium tuberculosis? Front Immunol (2017) 8:967. doi:10.3389/fimmu.2017.00967
125. Schierloh P, Yokobori N, Aleman M, Landoni V, Geffner L, Musella RM, et al. Mycobacterium tuberculosis-induced gamma interferon production by natural killer cells requires cross talk with antigen-presenting cells involving toll-like receptors 2 and 4 and the mannose receptor in tuberculous pleurisy. Infect Immun (2007) 75:5325-37. doi:10.1128/IAI.00381-07
126. Fu X, Yu S, Yang B, Lao S, Li B, Wu C. Memory-like antigen-specific human NK cells from TB pleural fluids produced IL-22 in response to IL-15 or Mycobacterium tuberculosis antigens. PLoS One (2016) 11:e0151721. doi:10.1371/journal.pone.0151721
127. Venkatasubramanian S, Cheekatla S, Paidipally P, Tripathi D, Welch E, Tvinnereim AR, et al. IL-21-dependent expansion of memory-like NK cells enhances protective immune responses against Mycobacterium tuberculosis. Mucosal Immunol (2017) 10:1031-42. doi:10.1038/mi.2016.105
128. Junqueira-Kipnis AP, Kipnis A, Jamieson A, Juarrero MG, Diefenbach A, Raulet DH, et al. NK cells respond to pulmonary infection with Mycobacterium tuberculosis, but play a minimal role in protection. J Immunol (2003) 171:6039-45. doi:10.4049/jimmunol.171.11.6039
129. Esin S, Batoni G. Natural killer cells: a coherent model for their functional role in Mycobacterium tuberculosis infection. J Innate Immun (2015) 7:11-24. doi:10.1159/000363321
130. Suliman S, Geldenhuys H, Johnson JL, Hughes JE, Smit E, Murphy M, et al. Bacillus Calmette-Guerin (BCG) revaccination of adults with latent Mycobacterium tuberculosis infection induces long-lived BCG-reactive NK cell responses. J Immunol (2016) 197:1100-10. doi:10.4049/jimmunol.1501996
131. Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Jacobs C, Xavier RJ, et al. BCG-induced trained immunity in NK cells: role for non-specific protection to infection. Clin Immunol (2014) 155:213-9. doi:10.1016/j.clim.2014.10.005
132. Netea MG, Quintin J, Van Der Meer JW. Trained immunity: a memory for innate host defense. Cell Host Microbe (2011) 9:355-61. doi:10.1016/j.chom.2011.04.006
133. Netea MG, van Crevel R. BCG-induced protection: effects on innate immune memory. Semin Immunol (2014) 26:512-7. doi:10.1016/j.smim.2014.09.006
134. Blok BA, Arts RJ, Van Crevel R, Benn CS, Netea MG. Trained innate immunity as underlying mechanism for the long-term, nonspecific effects of vaccines. J Leukoc Biol (2015) 98:347-56. doi:10.1189/jlb.5RI0315-096R
135. Arts RJW, Carvalho A, La Rocca C, Palma C, Rodrigues F, Silvestre R, et al. Immunometabolic pathways in BCG-induced trained immunity. Cell Rep (2016) 17:2562-71. doi:10.1016/j.celrep.2016.11.011
136. Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Ifrim DC, Saeed S, et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci U S A (2012) 109:17537-42. doi:10.1073/pnas.1202870109
137. Kagina BM, Abel B, Scriba TJ, Hughes EJ, Keyser A, Soares A, et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guerin vaccination of newborns. Am J Respir Crit Care Med (2010) 182:1073-9. doi:10.1164/rccm.201003-0334OC
138. Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg V, et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res (2009) 69:609-15. doi:10.1158/0008-5472.CAN-08-3529
139. Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res (2005) 65:1089-96
140. Mukherjee P, Basu GD, Tinder TL, Subramani DB, Bradley JM, Arefayene M, et al. Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. J Immunol (2009) 182:216-24. doi:10.4049/jimmunol.182.1.216
141. Basu GD, Tinder TL, Bradley JM, Tu T, Hattrup CL, Pockaj BA, et al. Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J Immunol (2006) 177:2391-402. doi:10.4049/jimmunol.177.4.2391
142. Inoue J, Aramaki Y. Cyclooxygenase-2 inhibition promotes enhancement of antitumor responses by transcutaneous vaccination with cytosine-phosphate-guanosine-oligodeoxynucleotides and model tumor antigen. J Invest Dermatol (2007) 127:614-21. doi:10.1038/sj.jid.5700656
143. Pettersen FO, Torheim EA, Dahm AE, Aaberge IS, Lind A, Holm M, et al. An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated immune activation and improved T cell-dependent vaccine responses. J Virol (2011) 85:6557-66. doi:10.1128/JVI.00073-11
144. Taus F, Santucci MB, Greco E, Morandi M, Palucci I, Mariotti S, et al. Monosodium urate crystals promote innate anti-mycobacterial immunity and improve BCG efficacy as a vaccine against tuberculosis. PLoS One (2015) 10:e0127279. doi:10.1371/journal.pone.0127279
145. Jagannath C, Lindsey DR, Dhandayuthapani S, Xu Y, Hunter RL Jr, Eissa NT. Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells. Nat Med (2009) 15:267-76. doi:10.1038/nm.1928
146. Cruz A, Fraga AG, Fountain JJ, Rangel-Moreno J, Torrado E, Saraiva M, et al. Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis. J Exp Med (2010) 207:1609-16. doi:10.1084/jem.20100265
147. Nambiar JK, Ryan AA, Kong CU, Britton WJ, Triccas JA. Modulation of pulmonary DC function by vaccine-encoded GM-CSF enhances protective immunity against Mycobacterium tuberculosis infection. Eur J Immunol (2010) 40:153-61. doi:10.1002/eji.200939665
148. O'Donnell MA, Aldovini A, Duda RB, Yang H, Szilvasi A, Young RA, et al. Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes. Infect Immun (1994) 62:2508-14